Chemomab Therapeutics (NASDAQ:CMMB) Price Target Raised to $7.00

Chemomab Therapeutics (NASDAQ:CMMB) had its target price hoisted by Maxim Group from $4.00 to $7.00 in a research report sent to investors on Thursday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Separately, Oppenheimer reiterated an “outperform” rating and set a $11.00 target price (down previously from $13.00) on shares of Chemomab Therapeutics in a report on Friday, November 15th.

Chemomab Therapeutics Trading Down 3.4 %

CMMB stock opened at $1.71 on Thursday. The stock has a 50-day moving average price of $1.97 and a two-hundred day moving average price of $1.71. The stock has a market cap of $24.56 million, a PE ratio of -1.71 and a beta of 0.66. Chemomab Therapeutics has a 1 year low of $0.58 and a 1 year high of $2.55.

Hedge Funds Weigh In On Chemomab Therapeutics

A number of large investors have recently modified their holdings of CMMB. Sphera Funds Management LTD. acquired a new position in shares of Chemomab Therapeutics during the 3rd quarter worth about $1,907,000. Virtu Financial LLC acquired a new position in shares of Chemomab Therapeutics during the 4th quarter worth about $26,000. Finally, XTX Topco Ltd boosted its stake in shares of Chemomab Therapeutics by 63.8% during the 4th quarter. XTX Topco Ltd now owns 24,929 shares of the company’s stock worth $45,000 after buying an additional 9,706 shares during the last quarter. 46.05% of the stock is currently owned by institutional investors and hedge funds.

About Chemomab Therapeutics

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).